[go: up one dir, main page]

EA200200536A1 - PEPTIDE ANALOGUES AND MIMETICS SUITABLE FOR IN VIVO APPLICATION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANOMALOUS PROTECTION OF PROTEINS IN AMYLOID OR AMYLOID-like DEPOSITIONS, OR THEIR PATHOLOGICAL PREMISCIENTEARCHEs, and their pathological precursiologi - Google Patents

PEPTIDE ANALOGUES AND MIMETICS SUITABLE FOR IN VIVO APPLICATION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANOMALOUS PROTECTION OF PROTEINS IN AMYLOID OR AMYLOID-like DEPOSITIONS, OR THEIR PATHOLOGICAL PREMISCIENTEARCHEs, and their pathological precursiologi

Info

Publication number
EA200200536A1
EA200200536A1 EA200200536A EA200200536A EA200200536A1 EA 200200536 A1 EA200200536 A1 EA 200200536A1 EA 200200536 A EA200200536 A EA 200200536A EA 200200536 A EA200200536 A EA 200200536A EA 200200536 A1 EA200200536 A1 EA 200200536A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amyloid
pathological
peptide
premiscientearches
precursiologi
Prior art date
Application number
EA200200536A
Other languages
Russian (ru)
Other versions
EA004739B1 (en
Inventor
Клаудио Сото-Яра
Original Assignee
Эксоникс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эксоникс, Инк. filed Critical Эксоникс, Инк.
Publication of EA200200536A1 publication Critical patent/EA200200536A1/en
Publication of EA004739B1 publication Critical patent/EA004739B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение предоставляет ингибиторный пептид, способный ингибировать образование β-складчатой структуры в амилоидном β-пептиде. Ингибиторный пептид представляет собой пептидный аналог, разрушающий β-складки, сконструированный путем химической модификации разрушающего β-складки пептида, способного ингибировать образование β-складчатой структуры в амилоидном β-пептиде. Настоящее изобретение также включает ингибиторный пептид, способный ингибировать конформационные изменения в прионовом белке PrP, связанные с амилоидозом. Ингибиторный пептид представляет собой пептидный аналог, разрушающий β-складки, сконструированный путем химической модификации разрушающего β-складки пептида, способного ингибировать конформационные изменения в прионовом белке PrP, связанные с амилоидозом. Кроме того, настоящее изобретение включает пептидомиметик, имеющий структуру PMiAβ5. В другом воплощении пептидомиметик имеет структуру PMiPrP13. В еще одном воплощении пептидомиметик имеет структуру PMiPrP5.The present invention provides an inhibitory peptide capable of inhibiting the formation of a β-folded structure in an amyloid β-peptide. An inhibitory peptide is a β-fold peptide analogue, constructed by chemical modification of a β-fold-destructing peptide capable of inhibiting the formation of a β-folded structure in an amyloid β-peptide. The present invention also includes an inhibitory peptide capable of inhibiting conformational changes in the prion protein PrP associated with amyloidosis. An inhibitory peptide is a β-fold peptide analogue, constructed by chemical modification of a β-fold-destructing peptide that can inhibit conformational changes in the prion protein PrP associated with amyloidosis. In addition, the present invention includes a peptidomimetic having the structure PMiAβ5. In another embodiment, the peptidomimetic has the structure PMiPrP13. In another embodiment, the peptidomimetic has the structure PMiPrP5.

EA200200536A 1999-11-05 2000-11-04 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES AS ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID-LIKE DEPOSITS OR beta-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF EA004739B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16391199P 1999-11-05 1999-11-05
PCT/US2000/030416 WO2001034631A2 (en) 1999-11-05 2000-11-04 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Publications (2)

Publication Number Publication Date
EA200200536A1 true EA200200536A1 (en) 2002-12-26
EA004739B1 EA004739B1 (en) 2004-08-26

Family

ID=22592138

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200536A EA004739B1 (en) 1999-11-05 2000-11-04 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES AS ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID-LIKE DEPOSITS OR beta-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF

Country Status (11)

Country Link
EP (1) EP1286590A4 (en)
JP (1) JP2004513873A (en)
KR (2) KR20060133114A (en)
CN (1) CN1437442A (en)
AU (1) AU781044B2 (en)
BR (1) BR0015513A (en)
CA (1) CA2389041A1 (en)
EA (1) EA004739B1 (en)
IL (1) IL149392A0 (en)
MX (1) MXPA02004468A (en)
WO (1) WO2001034631A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003612B2 (en) 1997-10-08 2011-08-23 Proteotech Inc. Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein disorders
DE10101430B4 (en) 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Soluble cyclic analogues for the modulation of amyloidogenesis
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
AU2004203461B2 (en) * 2002-01-31 2009-09-03 Tel Aviv University Future Technology Development L.P. Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
DE10230141B4 (en) * 2002-07-04 2004-07-15 Priontype Gmbh Method and kit for the enrichment and detection of modified prion proteins (PrPSc)
JP2006508904A (en) * 2002-07-08 2006-03-16 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ β-sheet breaking peptide
AU2003298260A1 (en) * 2002-12-02 2004-06-23 Laboratoires Serono Sa Aza-peptides
CA2530927A1 (en) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
EP2332971B1 (en) * 2004-06-17 2016-02-17 MannKind Corporation Epitope analogs
EP1858912B1 (en) * 2005-02-28 2012-04-11 Alphabeta AB Compounds for reducing aggregation of amyloid beta-peptide
CA2607940C (en) * 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
EP1746422A1 (en) * 2005-07-19 2007-01-24 Universita'degli Studi Di Milano Method for the identification of proteins folding inhibitors
KR20090047470A (en) * 2006-08-04 2009-05-12 론자 바이올로직스 피엘씨 How to predict protein aggregation and design aggregation inhibitors
MX2013005413A (en) 2010-11-15 2014-02-27 Univ Ramot Dipeptide analogs for treating conditions associated with amyloid fibril formation.
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
DK2776055T3 (en) * 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
DE102013016002A1 (en) * 2013-09-26 2015-03-26 Forschungszentrum Jülich GmbH Cyclic amyloid beta-binding peptides and their use
JP6660877B2 (en) * 2013-09-26 2020-03-11 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Amyloid-β-binding peptide and its use for the treatment and diagnosis of Alzheimer's dementia
MY179462A (en) * 2013-10-11 2020-11-06 Malaysian Palm Oil Board Protective effects of oil palm composition on alzheimer?s disease
KR101627106B1 (en) 2014-03-26 2016-06-03 연세대학교 산학협력단 polypeptide having multiple directionality and self-assembled nanostructure containing the same
DE102015003676A1 (en) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Specifically A-beta species-binding peptides for the therapy and / or diagnosis of Alzheimer's dementia
JP7699378B2 (en) 2018-05-15 2025-06-27 ハン ロイ トラン ロイド Therapeutic compositions and methods of use for the treatment of mild cognitive impairment, depression, and psychiatric disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
DK0929574T3 (en) * 1996-08-27 2005-10-31 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation which include D-amino acids

Also Published As

Publication number Publication date
KR20060133114A (en) 2006-12-22
JP2004513873A (en) 2004-05-13
EA004739B1 (en) 2004-08-26
CN1437442A (en) 2003-08-20
IL149392A0 (en) 2002-11-10
BR0015513A (en) 2004-07-06
EP1286590A2 (en) 2003-03-05
WO2001034631A3 (en) 2002-12-27
AU781044B2 (en) 2005-05-05
WO2001034631A2 (en) 2001-05-17
MXPA02004468A (en) 2004-09-10
EP1286590A4 (en) 2005-05-11
AU1463501A (en) 2001-06-06
CA2389041A1 (en) 2001-05-17
KR20020079731A (en) 2002-10-19

Similar Documents

Publication Publication Date Title
EA200200536A1 (en) PEPTIDE ANALOGUES AND MIMETICS SUITABLE FOR IN VIVO APPLICATION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANOMALOUS PROTECTION OF PROTEINS IN AMYLOID OR AMYLOID-like DEPOSITIONS, OR THEIR PATHOLOGICAL PREMISCIENTEARCHEs, and their pathological precursiologi
MXPA05010914A (en) Alzheimer's disease treatment method.
NO961326D0 (en) Inhibitors of
EA200602015A1 (en) HUMANIZED ANTIBODIES, RECOGNIZING BETA AMYLOID PEPTIDE
EA200101250A1 (en) PREVENTION AND THERAPY OF AMYLOIDOGENIC DISEASE
EA200501891A1 (en) HUMANIZED ANTIBODIES, RECOGNIZING BETA AMYLOID PEPTIDE
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
ATE344317T1 (en) SUBSTANCES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES
ATE438405T1 (en) USE OF ZONULIN PEPTIDE ANTAGONISTS FOR THE TREATMENT OF DIABETES
ATE394505T1 (en) PEPTIDE SCREENING TEST FOR DETECTING GAMMA SECRETASE ACTIVITY
ATE307143T1 (en) SOLUBLE CYCLIC ANALOGUE OF BETA AMYLOID PEPTIDE
EA200501528A1 (en) APPLICATION OF CLUSTERIN FOR THE TREATMENT AND / OR PREVENTION OF PERIPHERAL NEUROLOGICAL DISEASES
FR2858234B1 (en) NOVEL ANTI-ANGIOGENIC AGENT AND ITS USE, IN PARTICULAR IN THE TREATMENT OF CANCERS
WO2003050139A3 (en) Prion inhibiting peptides and derivatives thereof
DE60215219D1 (en) USE OF DARIFENACINE FOR THE TREATMENT OF THE HARNDRANGS
Critical Care Society of South Africa Working Group Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)
ATE275627T1 (en) HUMAN SITE-1 PROTEASE SPECIFIC PROMOTER